Compare ADMA Biologics Inc (ADMA) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Lowe`s Companies Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Lowe`s Companies Inc trades at $214.17 (market cap $123.86B). The key difference: Lowe`s Companies Inc is far larger — about 58.2× ADMA Biologics Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | LOW | |
|---|---|---|
Market Cap | $2.13B | $123.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $287.39 |
52-Week Low | $7.60 | $206.62 |
Enterprise Value | $2.20B | $165.61B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Lowe's (LOW) trades at $220.9, down 2.9% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 60.79% buy rating from analysts support optimism, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock's P/E of 18.92 and net income margin of 7.51% reflect solid profitability, while dividend increases counter earlier Wall Street skepticism about payout sustainability.
The outlook is positive with a $260.88 consensus price target, but risks include high debt levels, competitive pressure from Home Depot, and macroeconomic sensitivity. Earnings growth and professional market expansion are key catalysts, though inflation and housing market softness pose headwinds for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
